Literature DB >> 32367013

NLRP3 inflammasome activity as biomarker for primary progressive multiple sclerosis.

Sarah Lemprière1.   

Abstract

Entities:  

Year:  2020        PMID： 32367013     DOI： 10.1038/s41582-020-0366-y

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  1 in total

1.  NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients.

Authors:  Sunny Malhotra; Carme Costa; Herena Eixarch; Christian W Keller; Lukas Amman; Helios Martínez-Banaclocha; Luciana Midaglia; Eduard Sarró; Isabel Machín-Díaz; Luisa M Villar; Juan Carlos Triviño; Begoña Oliver-Martos; Laura Navarro Parladé; Laura Calvo-Barreiro; Fuencisla Matesanz; Koen Vandenbroeck; Elena Urcelay; María-Luisa Martínez-Ginés; Amalia Tejeda-Velarde; Nicolás Fissolo; Joaquín Castilló; Alex Sanchez; Avril A B Robertson; Diego Clemente; Marco Prinz; Pablo Pelegrin; Jan D Lünemann; Carmen Espejo; Xavier Montalban; Manuel Comabella
Journal:  Brain       Date:  2020-05-01       Impact factor: 13.501
  1 in total
  2 in total

1.  Targeted and activatable nanosystem for fluorescent and optoacoustic imaging of immune-mediated inflammatory diseases and therapy via inhibiting NF-κB/NLRP3 pathways.

Authors:  Lihe Sun; Juan Ouyang; Zhuo Zeng; Cheng Zeng; Yunqing Ma; Fang Zeng; Shuizhu Wu
Journal:  Bioact Mater       Date:  2021-08-11

2.  Highly sensitive Curcumin-conjugated nanotheranostic platform for detecting amyloid-beta plaques by magnetic resonance imaging and reversing cognitive deficits of Alzheimer's disease via NLRP3-inhibition.

Authors:  Yuting Ruan; Ying Xiong; Wenli Fang; Qun Yu; Yingren Mai; Zhiyu Cao; Kexi Wang; Ming Lei; Jiaxin Xu; Yan Liu; Xingcai Zhang; Wang Liao; Jun Liu
Journal:  J Nanobiotechnology       Date:  2022-07-14       Impact factor: 9.429
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.